Oklo stock tumbles as Financial Times scrutinizes valuation
Natera, Inc. (NASDAQ:NTRA), trading near its 52-week high of $187.34 and showing a remarkable 48% return over the past year, saw Co-Founder Sheena Jonathan dispose of 4,560 shares of common stock on October 15 and 17, in multiple transactions, according to a Form 4 filing with the Securities and Exchange Commission. According to InvestingPro analysis, the company maintains a "GREAT" financial health score. The sales, which totaled $807,041, occurred at weighted average prices ranging from $172.9918 to $179.3511 per share.
On October 15, Ms. Jonathan sold 153 shares at an average price of $172.9918, in a range of $172.75 to $173.48. She also sold 1,506 shares at an average price of $175.1097, in a range of $174.41 to $175.40, 988 shares at an average price of $175.8967, in a range of $175.41 to $176.40 and 423 shares at an average price of $176.6252, in a range of $176.59 to $176.63.
On October 17, Ms. Jonathan sold 475 shares held by Caraluna 1 Trust at an average price of $178.6601, in a range of $178.08 to $179.06, 275 shares held by Caraluna 1 Trust at an average price of $179.3511, in a range of $179.16 to $179.59, 413 shares held by Caraluna 2 Trust at an average price of $178.5818, in a range of $178.03 to $179.00 and 337 shares held by Caraluna 2 Trust at an average price of $179.2912, in a range of $179.03 to $179.64.
The sales were executed under a pre-arranged Rule 10b5-1 trading plan. With the stock currently appearing overvalued based on InvestingPro Fair Value calculations, investors seeking deeper insights can access 12 additional ProTips and comprehensive valuation metrics through the platform’s detailed research reports.
In other recent news, Natera, Inc. has continued to make significant strides in various medical research areas. The company has enrolled over 1,600 patients in its EXPAND trial, which is evaluating its Fetal Focus single gene noninvasive prenatal test for inherited conditions. This trial aims to confirm test results through prenatal or postnatal diagnostic testing. Additionally, Natera’s Signatera test has shown promising results in monitoring uterine cancer recurrence and treatment response, as well as outperforming standard markers in testicular cancer patient outcomes.
The company is set to present 14 abstracts at the upcoming European Society for Medical Oncology Congress to reinforce its leadership in molecular residual disease testing. In terms of stock analysis, Canaccord Genuity maintained its Buy rating and a price target of $200 for Natera, highlighting its advancements in early cancer detection. Meanwhile, Wells Fargo resumed coverage with an Equal Weight rating and a price target of $175, emphasizing Natera’s strong position in cell-free DNA testing technology. These developments underscore Natera’s ongoing efforts to innovate in the healthcare sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.